PRESS RELEASE
March 31, 2014, 4:37 p.m. EDT
Cytomedix Announces Senior Management Appointments
GAITHERSBURG, Mar 31, 2014 (GLOBE NEWSWIRE via COMTEX) -- Industry Veteran and Wound Care Commercial Expert Dean Tozer Appointed as Executive Vice President and Chief Commercial Officer
Jennifer Linsky Appointed as Senior Director of National Accounts
Cytomedix, Inc. (otcqx:CMXI), a leading developer of biologically active regenerative therapies, announced today the appointment of Dean Tozer as its Executive Vice President and Chief Commercial Officer. Mr. Tozer will be in charge of all commercial activity for AutoloGel and will lead the effort to drive product adoption in the estimated $3.4 billion U.S. wound care market. The Company also announced the appointment of Jennifer Linsky as its Senior Director of National Accounts.
Martin Rosendale, Chief Executive Officer of Cytomedix, commented, "Dean is one of the top professionals nationwide in the wound care specialty and has demonstrated exceptional ability in product commercialization. His appointment is a critical step in our efforts to build out the sales and marketing infrastructure for AutoloGel. In addition to his commercial and business development skills, he also brings in-depth knowledge of the reimbursement landscape and process, which is important to our growth. We look forward to the strategic insights and contributions he will make."
Mr. Rosendale added, "I would also like to welcome Jennifer Linsky to the team. Jennifer is a highly accomplished sales and marketing professional who has a demonstrated track record in building market share for healthcare products. She has significant experience in the wound care market and deep relationships with the major wound care management companies in the US. Her leadership skills and experience in wound care will be integral to AutoloGel brand building efforts."
Dean Tozer has more than 25 years' experience in the global healthcare industry and has an established track record of successfully launching and marketing wound care products. From 2006 - 2011 he was Senior Vice President at Advanced BioHealing Inc. where he was responsible for the acquisition and reintroduction of Dermagraftinto the U.S. market. Subsequently, Mr. Tozer became Vice President of Corporate Development at Shire Regenerative Medicine following the acquisition of Advanced BioHealing, where he led the business development efforts for that division including the 2012 acquisition of Pervasis Therapeutics. Prior to working at Shire, he served as a commercialization consultant to a variety of clients through independent consultancy Tozer & Associates. He also has eight years of global healthcare experience with Searle Pharmaceuticals, a Monsanto company. Mr. Tozer was also a founding executive and officer of the Alliance for Regenerative Medicine, where he served as Treasurer. He earned a Bachelor of Commerce degree from St. Mary's University in Halifax, Canada and is a Certified Management Accountant.
Jennifer Linsky also joins Cytomedix from Shire Regenerative Medicine, where she was a National Accounts Manager and National Manager of Market and Business Development. At Shire, she launched a business development and comprehensive disease management program initiative that increased the diabetic wound market potential nationwide. Ms. Linsky also spent more than 7 years in positions of increasing responsibility at GlaxoSmithKline, culminating in her promotion to a four-year position as a District Sales Manager. Ms. Linsky earned a Bachelor of Science in Nutritional Science/Pre-Medicine and graduated cum laude from Auburn University.
AI
